Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Trade Show, Webcast

Elpiscience to Participate in Cross-Pacific Collaboration Panel at BIO CEO & Investor Conference


Elpiscience Biopharmaceuticals, Inc. ("Elpiscience"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, today announced that its co-founder and chief executive officer, Dr. Darren Ji, will participate in a panel discussion about R&D and innovation leading cross-pacific collaboration. The conference takes place at the Marriott Marquis in New York City from February 14 to 15 and virtually through February 17, 2022.

The panel, titled "What is New in Cross-Pacific Deal Making and Investment?", will take place from 9:00 a.m. to 9:45 a.m. EST Wednesday, February 16, 2022, and will be accessible live to conference registrants.

A recorded Elpiscience presentation will also be available to registered attendees through the event platform beginning February 11.

For additional information, visit BIO CEO & Investor Conference.

About Elpiscience:

Elpiscience is a clinical stage biopharmaceutical company focused on innovating and developing next-generation immunotherapy to benefit cancer patients worldwide. The company has a robust pipeline of globally innovative molecules, covering wide range of targets in immuno-oncology. It has four molecules in clinical trials (ES002, ES101, ES102, and ES104), and endeavors to clinically advance at least one innovative molecule a year. Founded and managed by a team of biopharma industry leaders, Elpiscience is backed by renowned investors including, Lilly Asia Ventures, Hillhouse Capital, Hyfinity Investments, Greater Bay Area Homeland Development Fund, CDH, DYEE Capital and Cormorant Asset Management.

Learn more at elpiscience.com.


These press releases may also interest you

at 16:32
The wishes that Make-A-Wish grants wouldn't be possible without the support of countless "WishMakers" such as donors, volunteers, corporate partners, community advocates and more. "WishMakers" ? a term for anyone who steps up to take action...

at 16:30
Today, the Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, announced a new appointment to the Canadian Centre on Substance Use and Addiction (CCSA) Board of Directors. Scott Elliott is appointed as...

at 16:28
The Rett Syndrome Research Trust (RSRT) is proud to announce its partnership with PMD Solutions, a leading provider of innovative healthcare technologies, in their upcoming biosensor validation study called VIBRANT. PMD Solutions will generously...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31,...

at 16:20
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended...

at 16:20
Pulse Biosciences, Inc. , a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that its Board of Directors has unanimously approved plans to initiate a rights offering. The...



News published on and distributed by: